Prognostic Significance of Immunotherapy in Postoperative Recurrent Non-small Cell Lung Cancer Without EGFR Mutations or ALK Rearrangements

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Jul 10

PMID 38983180

Authors

Shunsuke Shigefuku

Satoshi Takahashi

Masaru Hagiwara

Masatoshi Kakihana

Tatsuo Ohira

Norihiko Ikeda

Affiliations

Soon will be listed here.

Abstract

Background: Limited reports exist regarding postoperative recurrent non-small cell lung cancer (NSCLC) without major driver mutations [epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements] treated with immune checkpoint inhibitors (ICIs) when programmed cell death ligand 1 (PD-L1) is expressed in a real-world setting. The aim of this study was to evaluate the effect of ICIs for those NSCLC.

Methods: We enrolled 255 patients with postoperative recurrent NSCLC lacking EGFR mutations or ALK rearrangements who underwent lobectomy or more extensive resection between 2012 and 2021. Factors associated with post-recurrence survival (PRS) were determined using the Cox proportional hazards model. PRS was analyzed using Kaplan-Meier curves and compared using the log-rank test.

Results: Multivariable analysis demonstrated that squamous cell carcinoma, pathological stage III, and an Eastern Cooperative Oncology Group (ECOG) performance status ≥2 were significantly associated with worse PRS. Conversely, ICI use at first line was associated with improved PRS. Patients who used ICIs during the first line and subsequent therapies had better PRS than those who received chemotherapy alone. Among patients who used ICIs, there was no significant difference in response rate at the first line, nor in PRS among those with PD-L1 expression ≥50%, 1-49%, and <1% in surgically resected specimens.

Conclusions: ICI use at any treatment line improved the PRS of NSCLC patients without major driver mutations, irrespective of PD-L1 expression, in a real-world setting.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Sun J, Zhou W, Choi Y, Choi S, Kim S, Wang Z . Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. J Thorac Oncol. 2016; 11(7):1003-11. DOI: 10.1016/j.jtho.2016.04.007. View

Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y . Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2023; 71(9):534-541. DOI: 10.1007/s11748-023-01920-z. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K . Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg. 1994; 108(1):158-61. View

Houston K, Mitchell K, King J, White A, Ryan B . Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County. J Thorac Oncol. 2018; 13(4):497-509. PMC: 5884169. DOI: 10.1016/j.jtho.2017.12.010. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Shima Y, Sato Y, Morimoto T, Hara S, Hirabayashi R, Nagata K . Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. Invest New Drugs. 2022; 41(1):35-43. DOI: 10.1007/s10637-022-01309-4. View

Uramoto H, Tanaka F . Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2015; 3(4):242-9. PMC: 4367696. DOI: 10.3978/j.issn.2218-6751.2013.12.05. View

10.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

11.

Hashimoto K, Ariyasu R, Ichinose J, Matsuura Y, Nakao M, Amino Y . Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients. J Thorac Cardiovasc Surg. 2022; 165(4):1565-1574.e1. DOI: 10.1016/j.jtcvs.2022.08.014. View

12.

Arbour K, Riely G . Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019; 322(8):764-774. DOI: 10.1001/jama.2019.11058. View

13.

Xu Y, Wan B, Chen X, Zhan P, Zhao Y, Zhang T . The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019; 8(4):413-428. PMC: 6749123. DOI: 10.21037/tlcr.2019.08.09. View

14.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

15.

Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M . Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn. 2006; 8(4):504-12. PMC: 1867624. DOI: 10.2353/jmoldx.2006.060030. View

16.

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

17.

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

18.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

19.

Matsuura Y, Ninomiya H, Ichinose J, Nakao M, Okumura S, Nishio M . Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma. J Thorac Cardiovasc Surg. 2020; 163(2):441-451.e1. DOI: 10.1016/j.jtcvs.2020.09.120. View

20.

Sugimura H, Nichols F, Yang P, Allen M, Cassivi S, Deschamps C . Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007; 83(2):409-17. DOI: 10.1016/j.athoracsur.2006.08.046. View